Aptargroup INC: directors' dealings · United States · SEC (Form 4)

About Aptargroup INC

AptarGroup Inc. (NYSE: ATR) is a U.S.-based industrial company headquartered in Crystal Lake, Illinois, United States. Founded in 1992, with roots that go back much further through predecessor businesses in metalworking and dispensing technologies, Aptar has built a global franchise in dosing, dispensing, and protection technologies for packaging and drug-delivery applications. The company employs roughly 14,000 people across about 20 countries, underscoring a broad international manufacturing and commercial footprint that supports customers in healthcare, beauty, and consumer goods. ([aptar.com](https://aptar.com/en-us/about-aptar?utm_source=openai)) Aptar operates through three main segments: Pharma, Beauty, and Closures. Pharma is the company’s most strategically important engine, covering nasal spray systems, inhalation components, oral dosing solutions, injectable components, and related drug-development services. Beauty serves fragrance, skincare, color cosmetics, and personal-care markets with pumps, valves, aerosol actuators, and airless dispensing systems. Closures provides dispensing and closure solutions for food, beverage, home care, and other consumer applications. This mix gives Aptar a balanced exposure to both healthcare and consumer end markets, while supporting a relatively resilient revenue base. ([stockanalysis.com](https://stockanalysis.com/stocks/atr/company/?utm_source=openai)) From a competitive standpoint, Aptar positions itself as a technology-led supplier rather than a commoditized packaging manufacturer. Its moat is built on proprietary engineering, materials science, regulatory know-how, and deep collaboration with global brand owners and pharmaceutical companies. In pharma, Aptar has established strong credibility in nasal and pulmonary delivery platforms, where precision, patient usability, and regulatory compliance are critical. In beauty and consumer dispensing, the company benefits from long-standing relationships with major brands and from demand for premium, differentiated packaging formats. ([aptar.com](https://aptar.com/en-us/about-aptar?utm_source=openai)) Recent developments point to continued innovation and disciplined capital allocation. In 2025, Aptar announced a clinical validation study for its SmartTrack™ in-vitro-in-silico platform, which is designed to help accelerate FDA approval pathways for certain pressurized metered-dose inhalers. The company also released its 2024 Sustainability Report, highlighting environmental and circularity initiatives. More recently, Aptar completed targeted acquisitions to strengthen its pharma capabilities and support oral dosing and clinical-trial materials manufacturing. Its 2025 full-year results showed earnings growth and included a new $600 million share repurchase authorization, which is notable for investors focused on shareholder returns. Overall, Aptar is a quality industrial compounder with a global presence, a defensible niche in drug delivery, and a stock listed on the NYSE in the United States. ([investors.aptar.com](https://investors.aptar.com/news/news-details/2025/Aptar-Announces-Clinical-Validation-Study-to-Accelerate-US-FDA-Approval-of-SmartTrack-In-Vitro-in-Silico-Platform-for-Pressurized-Metered-Dose-Inhalers/default.aspx?utm_source=openai))